Q2-FY26 · Kiran Divi
We have not lost a single customer or even a any loss in volume.
DIVISLAB / language trends
Read confidence between the lines.
Divi's Laboratories · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q2-FY26 · Kiran Divi
DIS has strategically decided that we will not look at generic part of peptide synthesis. We are right now fully occupied with the amount of CS projects we have.
Q2-FY26 · Kiran Divi
I cannot put a label saying this is API or peptide or specific therapeutic category. All I can say is it belongs to a CS side of the business and we believe if all regulatory approvals and qualifications take place on time in the next one to two years you should see commercial benefit.
Q3-FY26 · Dr. Kiran S
As our managing director would say, the sky is the limit for you to dream.
Q3-FY26 · Dr. Kiran S
We have increased the use of process automation and multiple new chemistry platforms, scaling them into commercial manufacturing to improve process safety, minimize heat buildup for a more sustainable process.
Q3-FY26 · Nellima Madhavi
We are not hedging; we are evaluating at this point based on the overall scenario in the market.